<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240717061037&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;ff=20240717061037&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 17 Jul 2024 10:10:39 +0000</lastbuilddate>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Lifelong impact of adiposity on cardiac structure and function: an alarming signal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39013546/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae443. doi: 10.1093/eurheartj/ehae443. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39013546/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39013546</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae443>10.1093/eurheartj/ehae443</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39013546</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Leonardo Roever</dc:creator>
<dc:creator>Gary Tse</dc:creator>
<dc:creator>Giuseppe Biondi-Zoccai</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Lifelong impact of adiposity on cardiac structure and function: an alarming signal</dc:title>
<dc:identifier>pmid:39013546</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae443</dc:identifier>
</item>
<item>
<title>Adulthood adiposity affects cardiac structure and function in later life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39013477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Higher adiposity (BMI/WHR) over adulthood is associated with evidence of adverse cardiac structure and function. Some of these associations are independent of adiposity in later life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae403. doi: 10.1093/eurheartj/ehae403. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Excess adiposity is associated with poorer cardiac function and adverse left ventricular (LV) remodelling. However, its importance over the adult life course on future cardiac structure and systolic and diastolic function is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 1690 participants in the National Survey of Health and Development birth cohort underwent repeated adiposity [body mass index (BMI)/waist-to-hip ratio (WHR)] measurements over adulthood and investigation, including echocardiography at age 60-64 years. The relationship between LV structure [LV mass (LVM), relative wall thickness, and LV internal diameter in diastole (LVIDd)] and function (diastolic: E/e', e', and left atrial volume indexed to body surface area; systolic: ejection fraction, S', and myocardial contraction fraction) was investigated using multivariable linear regression models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Increased BMI from age 20 years onwards was associated with greater LVM and LVIDd independent of confounders. Associations remained independent of current BMI for LVIDd and at age 26, 43, and 53 years for LVM. Increased BMI from 43 years onwards was associated with greater relative wall thickness, but not when BMI at age 60-64 years was accounted for. Increased BMI at age 26, 36, and 53 years and at 20 years onwards was associated with lower ejection fraction and myocardial contraction fraction, respectively, but not independently of BMI at 60-64 years. Higher BMI from 20 years onwards was associated with poorer diastolic function independent of confounders. Associations between BMI and left atrial volume indexed to body surface area persisted from 26 years onwards after adjustment for BMI at 60-64 years. Similar relationships were observed for WHR from age 43 years onwards.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Higher adiposity (BMI/WHR) over adulthood is associated with evidence of adverse cardiac structure and function. Some of these associations are independent of adiposity in later life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39013477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39013477</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae403>10.1093/eurheartj/ehae403</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39013477</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lamia Al Saikhan</dc:creator>
<dc:creator>Nish Chaturvedi</dc:creator>
<dc:creator>Arjun K Ghosh</dc:creator>
<dc:creator>Rebecca Hardy</dc:creator>
<dc:creator>Alun Hughes</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adulthood adiposity affects cardiac structure and function in later life</dc:title>
<dc:identifier>pmid:39013477</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae403</dc:identifier>
</item>
<item>
<title>Integrated cryoEM structure of a spumaretrovirus reveals cross-kingdom evolutionary relationships and the molecular basis for assembly and virus entry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39013471/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>Foamy viruses (FVs) are an ancient lineage of retroviruses, with an evolutionary history spanning over 450 million years. Vector systems based on Prototype Foamy Virus (PFV) are promising candidates for gene and oncolytic therapies. Structural studies of PFV contribute to the understanding of the mechanisms of FV replication, cell entry and infection, and retroviral evolution. Here we combine cryoEM and cryoET to determine high-resolution in situ structures of the PFV icosahedral capsid (CA) and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 6:S0092-8674(24)00657-3. doi: 10.1016/j.cell.2024.06.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Foamy viruses (FVs) are an ancient lineage of retroviruses, with an evolutionary history spanning over 450 million years. Vector systems based on Prototype Foamy Virus (PFV) are promising candidates for gene and oncolytic therapies. Structural studies of PFV contribute to the understanding of the mechanisms of FV replication, cell entry and infection, and retroviral evolution. Here we combine cryoEM and cryoET to determine high-resolution in situ structures of the PFV icosahedral capsid (CA) and envelope glycoprotein (Env), including its type III transmembrane anchor and membrane-proximal external region (MPER), and show how they are organized in an integrated structure of assembled PFV particles. The atomic models reveal an ancient retroviral capsid architecture and an unexpected relationship between Env and other class 1 fusion proteins of the Mononegavirales. Our results represent the de novo structure determination of an assembled retrovirus particle.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39013471/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39013471</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.017>10.1016/j.cell.2024.06.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39013471</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas Calcraft</dc:creator>
<dc:creator>Nicole Stanke-Scheffler</dc:creator>
<dc:creator>Andrea Nans</dc:creator>
<dc:creator>Dirk Lindemann</dc:creator>
<dc:creator>Ian A Taylor</dc:creator>
<dc:creator>Peter B Rosenthal</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Integrated cryoEM structure of a spumaretrovirus reveals cross-kingdom evolutionary relationships and the molecular basis for assembly and virus entry</dc:title>
<dc:identifier>pmid:39013471</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.017</dc:identifier>
</item>
<item>
<title>Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39013470/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its application. Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejection and treated one patient with refractory immune-mediated necrotizing myopathy and two patients with diffuse cutaneous systemic sclerosis with these cells. This study...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 9:S0092-8674(24)00701-3. doi: 10.1016/j.cell.2024.06.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Allogeneic chimeric antigen receptor (CAR)-T cells hold great promise for expanding the accessibility of CAR-T therapy, whereas the risks of allograft rejection have hampered its application. Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejection and treated one patient with refractory immune-mediated necrotizing myopathy and two patients with diffuse cutaneous systemic sclerosis with these cells. This study was registered at ClinicalTrials.gov (NCT05859997). The infused cells persisted for over 3 months, achieving complete B cell depletion within 2 weeks of treatment. During the 6-month follow-up, we observed deep remission without cytokine release syndrome or other serious adverse events in all three patients, primarily shown by the significant improvement in the clinical response index scores for the two diseases, respectively, and supported by the observations of reversal of inflammation and fibrosis. Our results demonstrate the high safety and promising immune modulatory effect of the off-the-shelf CAR-T cells in treating severe refractory autoimmune diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39013470/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39013470</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.027>10.1016/j.cell.2024.06.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39013470</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaobing Wang</dc:creator>
<dc:creator>Xin Wu</dc:creator>
<dc:creator>Binghe Tan</dc:creator>
<dc:creator>Liang Zhu</dc:creator>
<dc:creator>Yi Zhang</dc:creator>
<dc:creator>Li Lin</dc:creator>
<dc:creator>Yi Xiao</dc:creator>
<dc:creator>An Sun</dc:creator>
<dc:creator>Xinyi Wan</dc:creator>
<dc:creator>Shiyuan Liu</dc:creator>
<dc:creator>Yanfang Liu</dc:creator>
<dc:creator>Na Ta</dc:creator>
<dc:creator>Hang Zhang</dc:creator>
<dc:creator>Jialin Song</dc:creator>
<dc:creator>Ting Li</dc:creator>
<dc:creator>Ling Zhou</dc:creator>
<dc:creator>Jian Yin</dc:creator>
<dc:creator>Lingying Ye</dc:creator>
<dc:creator>Hongjuan Lu</dc:creator>
<dc:creator>Jinwei Hong</dc:creator>
<dc:creator>Hui Cheng</dc:creator>
<dc:creator>Ping Wang</dc:creator>
<dc:creator>Weiqing Li</dc:creator>
<dc:creator>Jianfeng Chen</dc:creator>
<dc:creator>Jin Zhang</dc:creator>
<dc:creator>Jing Luo</dc:creator>
<dc:creator>Miaozhen Huang</dc:creator>
<dc:creator>Lehang Guo</dc:creator>
<dc:creator>Xiaoming Pan</dc:creator>
<dc:creator>Yi Jin</dc:creator>
<dc:creator>Wenjing Ye</dc:creator>
<dc:creator>Lie Dai</dc:creator>
<dc:creator>Jian Zhu</dc:creator>
<dc:creator>Lingyun Sun</dc:creator>
<dc:creator>Biao Zheng</dc:creator>
<dc:creator>Dali Li</dc:creator>
<dc:creator>Yanran He</dc:creator>
<dc:creator>Mingyao Liu</dc:creator>
<dc:creator>Huaxiang Wu</dc:creator>
<dc:creator>Bing Du</dc:creator>
<dc:creator>Huji Xu</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis</dc:title>
<dc:identifier>pmid:39013470</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.027</dc:identifier>
</item>
<item>
<title>The WDR11 complex is a receptor for acidic-cluster-containing cargo proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39013469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>Vesicle trafficking is a fundamental process that allows for the sorting and transport of specific proteins (i.e., "cargoes") to different compartments of eukaryotic cells. Cargo recognition primarily occurs through coats and the associated proteins at the donor membrane. However, it remains unclear whether cargoes can also be selected at other stages of vesicle trafficking to further enhance the fidelity of the process. The WDR11-FAM91A1 complex functions downstream of the clathrin-associated...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 28:S0092-8674(24)00698-6. doi: 10.1016/j.cell.2024.06.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Vesicle trafficking is a fundamental process that allows for the sorting and transport of specific proteins (i.e., "cargoes") to different compartments of eukaryotic cells. Cargo recognition primarily occurs through coats and the associated proteins at the donor membrane. However, it remains unclear whether cargoes can also be selected at other stages of vesicle trafficking to further enhance the fidelity of the process. The WDR11-FAM91A1 complex functions downstream of the clathrin-associated AP-1 complex to facilitate protein transport from endosomes to the TGN. Here, we report the cryo-EM structure of human WDR11-FAM91A1 complex. WDR11 directly and specifically recognizes a subset of acidic clusters, which we term super acidic clusters (SACs). WDR11 complex assembly and its binding to SAC-containing proteins are indispensable for the trafficking of SAC-containing proteins and proper neuronal development in zebrafish. Our studies thus uncover that cargo proteins could be recognized in a sequence-specific manner downstream of a protein coat.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39013469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39013469</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.024>10.1016/j.cell.2024.06.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39013469</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Huaqing Deng</dc:creator>
<dc:creator>Guowen Jia</dc:creator>
<dc:creator>Ping Li</dc:creator>
<dc:creator>Yingying Tang</dc:creator>
<dc:creator>Lin Zhao</dc:creator>
<dc:creator>Qin Yang</dc:creator>
<dc:creator>Jia Zhao</dc:creator>
<dc:creator>Jinrui Wang</dc:creator>
<dc:creator>Yingfeng Tu</dc:creator>
<dc:creator>Xin Yong</dc:creator>
<dc:creator>Sitao Zhang</dc:creator>
<dc:creator>Xianming Mo</dc:creator>
<dc:creator>Daniel D Billadeau</dc:creator>
<dc:creator>Zhaoming Su</dc:creator>
<dc:creator>Da Jia</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The WDR11 complex is a receptor for acidic-cluster-containing cargo proteins</dc:title>
<dc:identifier>pmid:39013469</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.024</dc:identifier>
</item>
<item>
<title>Intraplaque haemorrhage, coronary spasm, and resuscitated cardiac arrest in patients with non-obstructive coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae460. doi: 10.1093/eurheartj/ehae460. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011788</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae460>10.1093/eurheartj/ehae460</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011788</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Takeshi Nishi</dc:creator>
<dc:creator>Teruyoshi Kume</dc:creator>
<dc:creator>Yuichi Saito</dc:creator>
<dc:creator>Ken Kato</dc:creator>
<dc:creator>Kazuya Tateishi</dc:creator>
<dc:creator>Ryotaro Yamada</dc:creator>
<dc:creator>Hideki Kitahara</dc:creator>
<dc:creator>Yoji Neishi</dc:creator>
<dc:creator>Yoshio Kobayashi</dc:creator>
<dc:creator>Shiro Uemura</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intraplaque haemorrhage, coronary spasm, and resuscitated cardiac arrest in patients with non-obstructive coronary artery disease</dc:title>
<dc:identifier>pmid:39011788</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae460</dc:identifier>
</item>
<item>
<title>Cardiac wasting and cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae438. doi: 10.1093/eurheartj/ehae438. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae438>10.1093/eurheartj/ehae438</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011778</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Markus S Anker</dc:creator>
<dc:creator>Tienush Rassaf</dc:creator>
<dc:creator>José L Zamorano</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac wasting and cancer</dc:title>
<dc:identifier>pmid:39011778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae438</dc:identifier>
</item>
<item>
<title>Mechanical mitral valve obstruction: gone with the wind</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae431. doi: 10.1093/eurheartj/ehae431. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011683</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae431>10.1093/eurheartj/ehae431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011683</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jie Wang</dc:creator>
<dc:creator>Ping Hu</dc:creator>
<dc:creator>Xiao-Jing Ma</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mechanical mitral valve obstruction: gone with the wind</dc:title>
<dc:identifier>pmid:39011683</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae431</dc:identifier>
</item>
<item>
<title>Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify glucagon receptor signaling in cardiomyocytes as a critical determinant of HFpEF progression and provide proof-of-concept support for glucagon receptor antagonism as a potential therapy for the disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 16. doi: 10.1161/CIRCRESAHA.124.324706. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is an emerging major unmet need and one of the most significant clinic challenges in cardiology. The pathogenesis of HFpEF is associated with multiple risk factors. Hypertension and metabolic disorders associated with obesity are the 2 most prominent comorbidities observed in patients with HFpEF. Although hypertension-induced mechanical overload has long been recognized as a potent contributor to heart failure with reduced ejection fraction, the synergistic interaction between mechanical overload and metabolic disorders in the pathogenesis of HFpEF remains poorly characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHOD: We investigated the functional outcome and the underlying mechanisms from concurrent mechanic and metabolic stresses in the heart by applying transverse aortic constriction in lean C57Bl/6J or obese/diabetic B6.Cg-Lep<sup>ob</sup>/J (ob/ob) mice, followed by single-nuclei RNA-seq and targeted manipulation of a top-ranked signaling pathway differentially affected in the 2 experimental cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In contrast to the post-trans-aortic constriction C57Bl/6J lean mice, which developed pathological features of heart failure with reduced ejection fraction over time, the post-trans-aortic constriction ob/ob mice showed no significant changes in ejection fraction but developed characteristic pathological features of HFpEF, including diastolic dysfunction, worsened cardiac hypertrophy, and pathological remodeling, along with further deterioration of exercise intolerance. Single-nuclei RNA-seq analysis revealed significant transcriptome reprogramming in the cardiomyocytes stressed by both pressure overload and obesity/diabetes, markedly distinct from the cardiomyocytes singularly stressed by pressure overload or obesity/diabetes. Furthermore, glucagon signaling was identified as the top-ranked signaling pathway affected in the cardiomyocytes associated with HFpEF. Treatment with a glucagon receptor antagonist significantly ameliorated the progression of HFpEF-related pathological features in 2 independent preclinical models. Importantly, cardiomyocyte-specific genetic deletion of the glucagon receptor also significantly improved cardiac function in response to pressure overload and metabolic stress.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify glucagon receptor signaling in cardiomyocytes as a critical determinant of HFpEF progression and provide proof-of-concept support for glucagon receptor antagonism as a potential therapy for the disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011638</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324706>10.1161/CIRCRESAHA.124.324706</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011638</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Chen Gao</dc:creator>
<dc:creator>Zhaojun Xiong</dc:creator>
<dc:creator>Yunxia Liu</dc:creator>
<dc:creator>Meng Wang</dc:creator>
<dc:creator>Menglong Wang</dc:creator>
<dc:creator>Tian Liu</dc:creator>
<dc:creator>Jianfang Liu</dc:creator>
<dc:creator>Shuxun Ren</dc:creator>
<dc:creator>Nancy Cao</dc:creator>
<dc:creator>Hai Yan</dc:creator>
<dc:creator>Daniel J Drucker</dc:creator>
<dc:creator>Christoph Daniel Rau</dc:creator>
<dc:creator>Tomohiro Yokota</dc:creator>
<dc:creator>Jijun Huang</dc:creator>
<dc:creator>Yibin Wang</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39011638</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324706</dc:identifier>
</item>
<item>
<title>Dysferlin Enables Tubular Membrane Proliferation in Cardiac Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Dysferlin represents a new molecular target in cardiac disease that protects the integrity of tubule-sarcoplasmic reticulum junctional complexes for regulated excitation-contraction coupling and controls TAT network reorganization and tubular membrane proliferation in cardiomyocyte hypertrophy induced by pressure overload.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 16. doi: 10.1161/CIRCRESAHA.124.324588. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy compensates for increased biomechanical stress of the heart induced by prevalent cardiovascular pathologies but can result in cardiac failure if left untreated. We hypothesized that the tail-anchored protein dysferlin with multiple Ca<sup>2+</sup>-binding C<sub>2</sub>-domains is critical for the integrity of the transverse-axial tubule (TAT) network inside cardiomyocytes and contributes to the proliferation of TAT endomembranes during pressure overload-induced cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To reveal the impact of the membrane fusion and repair protein dysferlin on TAT network stabilization and proliferation necessary for the hypertrophic growth of cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: Super-resolution light and electron microscopy of mouse cardiomyocytes identified a specific localization of dysferlin in a vesicular compartment in nanometric proximity to contact sites of the TAT network with the sarcoplasmic reticulum, a.k.a. junctional complexes for Ca<sup>2+</sup>-induced Ca<sup>2+</sup> release. Mass spectrometry was used to characterize the cardiac dysferlin interactome, thereby identifying a novel protein interaction with the membrane-tethering sarcoplasmic reticulum protein juncophilin-2, a putative interactor of L-type Ca<sup>2+</sup> channels and ryanodine receptor Ca<sup>2+</sup> release channels in junctional complexes. While the dysferlin knockout caused a mild progressive phenotype of dilated cardiomyopathy in the mouse heart, global proteome analysis revealed changes preceding systolic failure. Following transverse aortic constriction, dysferlin protein expression was significantly increased in hypertrophied wild-type myocardium, while dysferlin knockout animals presented markedly reduced left-ventricular hypertrophy. Live-cell membrane imaging demonstrated a profound reorganization of the TAT network in wild-type left-ventricular myocytes post-transverse aortic constriction with robust proliferation of axial tubules, which critically depended on the increased expression of dysferlin within newly emerging tubule components.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Dysferlin represents a new molecular target in cardiac disease that protects the integrity of tubule-sarcoplasmic reticulum junctional complexes for regulated excitation-contraction coupling and controls TAT network reorganization and tubular membrane proliferation in cardiomyocyte hypertrophy induced by pressure overload.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011635</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324588>10.1161/CIRCRESAHA.124.324588</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011635</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nora Josefine Paulke</dc:creator>
<dc:creator>Carolin Fleischhacker</dc:creator>
<dc:creator>Justus B Wegener</dc:creator>
<dc:creator>Gabriel C Riedemann</dc:creator>
<dc:creator>Constantin Cretu</dc:creator>
<dc:creator>Mufassra Mushtaq</dc:creator>
<dc:creator>Nina Zaremba</dc:creator>
<dc:creator>Wiebke Möbius</dc:creator>
<dc:creator>Yannik Zühlke</dc:creator>
<dc:creator>Jasper Wedemeyer</dc:creator>
<dc:creator>Lorenz Liebmann</dc:creator>
<dc:creator>Anastasiia A Gorshkova</dc:creator>
<dc:creator>Daniel Kownatzki-Danger</dc:creator>
<dc:creator>Eva Wagner</dc:creator>
<dc:creator>Tobias Kohl</dc:creator>
<dc:creator>Carolin Wichmann</dc:creator>
<dc:creator>Olaf Jahn</dc:creator>
<dc:creator>Henning Urlaub</dc:creator>
<dc:creator>Karl Toischer</dc:creator>
<dc:creator>Gerd Hasenfuß</dc:creator>
<dc:creator>Tobias Moser</dc:creator>
<dc:creator>Julia Preobraschenski</dc:creator>
<dc:creator>Christof Lenz</dc:creator>
<dc:creator>Eva A Rog-Zielinska</dc:creator>
<dc:creator>Stephan E Lehnart</dc:creator>
<dc:creator>Sören Brandenburg</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Dysferlin Enables Tubular Membrane Proliferation in Cardiac Hypertrophy</dc:title>
<dc:identifier>pmid:39011635</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324588</dc:identifier>
</item>
<item>
<title>A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011630/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The DSP risk score is a novel model that leverages readily available clinical parameters to provide individualized VA risk assessment for DSP patients. This tool may help guide decision-making for primary prevention implantable cardioverter-defibrillator placement in this high-risk population and supports a gene-first risk stratification approach.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae409. doi: 10.1093/eurheartj/ehae409. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Pathogenic desmoplakin (DSP) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized arrhythmic risk assessment have proven unreliable in this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients from the multi-national DSP-ERADOS (Desmoplakin SPecific Effort for a RAre Disease Outcome Study) Network patient registry who had pathogenic or likely pathogenic DSP variants and no sustained VA prior to enrolment were followed longitudinally for the development of first sustained VA event. Clinically guided, step-wise Cox regression analysis was used to develop a novel clinical tool predicting the development of incident VA. Model performance was assessed by c-statistic in both the model development cohort (n = 385) and in an external validation cohort (n = 86).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 471 DSP patients [mean age 37.8 years, 65.6% women, 38.6% probands, 26% with left ventricular ejection fraction (LVEF) &lt; 50%] were followed for a median of 4.0 (interquartile range: 1.6-7.3) years; 71 experienced first sustained VA events {2.6% [95% confidence interval (CI): 2.0, 3.5] events/year}. Within the development cohort, five readily available clinical parameters were identified as independent predictors of VA and included in a novel DSP risk score: female sex [hazard ratio (HR) 1.9 (95% CI: 1.1-3.4)], history of non-sustained ventricular tachycardia [HR 1.7 (95% CI: 1.1-2.8)], natural logarithm of 24-h premature ventricular contraction burden [HR 1.3 (95% CI: 1.1-1.4)], LVEF &lt; 50% [HR 1.5 (95% CI: .95-2.5)], and presence of moderate to severe right ventricular systolic dysfunction [HR 6.0 (95% CI: 2.9-12.5)]. The model demonstrated good risk discrimination within both the development [c-statistic .782 (95% CI: .77-.80)] and external validation [c-statistic .791 (95% CI: .75-.83)] cohorts. The negative predictive value for DSP patients in the external validation cohort deemed to be at low risk for VA (&lt;5% at 5 years; n = 26) was 100%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The DSP risk score is a novel model that leverages readily available clinical parameters to provide individualized VA risk assessment for DSP patients. This tool may help guide decision-making for primary prevention implantable cardioverter-defibrillator placement in this high-risk population and supports a gene-first risk stratification approach.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011630/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011630</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae409>10.1093/eurheartj/ehae409</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011630</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Richard T Carrick</dc:creator>
<dc:creator>Alessio Gasperetti</dc:creator>
<dc:creator>Alexandros Protonotarios</dc:creator>
<dc:creator>Brittney Murray</dc:creator>
<dc:creator>Mikael Laredo</dc:creator>
<dc:creator>Iris van der Schaaf</dc:creator>
<dc:creator>Dennis Dooijes</dc:creator>
<dc:creator>Petros Syrris</dc:creator>
<dc:creator>Douglas Cannie</dc:creator>
<dc:creator>Crystal Tichnell</dc:creator>
<dc:creator>Nisha A Gilotra</dc:creator>
<dc:creator>Chiara Cappelletto</dc:creator>
<dc:creator>Kristen Medo</dc:creator>
<dc:creator>Ardan M Saguner</dc:creator>
<dc:creator>Firat Duru</dc:creator>
<dc:creator>Robyn J Hylind</dc:creator>
<dc:creator>Dominic J Abrams</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Mattia Targetti</dc:creator>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Maddalena Graziosi</dc:creator>
<dc:creator>Moniek Cox</dc:creator>
<dc:creator>Elena Biagini</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Paolo Compagnucci</dc:creator>
<dc:creator>Michela Casella</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Claudio Tondo</dc:creator>
<dc:creator>Momina Yazdani</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Sanjay K Prasad</dc:creator>
<dc:creator>Leonardo Calò</dc:creator>
<dc:creator>Eric D Smith</dc:creator>
<dc:creator>Adam S Helms</dc:creator>
<dc:creator>Sophie Hespe</dc:creator>
<dc:creator>Jodie Ingles</dc:creator>
<dc:creator>Harikrishna Tandri</dc:creator>
<dc:creator>Flavie Ader</dc:creator>
<dc:creator>Giovanni Peretto</dc:creator>
<dc:creator>Stacey Peters</dc:creator>
<dc:creator>Ari Horton</dc:creator>
<dc:creator>Jessica Yao</dc:creator>
<dc:creator>Eric Schulze-Bahr</dc:creator>
<dc:creator>Sven Dittman</dc:creator>
<dc:creator>Eric D Carruth</dc:creator>
<dc:creator>Katelyn Young</dc:creator>
<dc:creator>Maria Qureshi</dc:creator>
<dc:creator>Chris Haggerty</dc:creator>
<dc:creator>Victoria N Parikh</dc:creator>
<dc:creator>Matthew Taylor</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Arthur Wilde</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Marco Merlo</dc:creator>
<dc:creator>Estelle Gandjbakhch</dc:creator>
<dc:creator>J Peter van Tintelen</dc:creator>
<dc:creator>Anneline S J M Te Riele</dc:creator>
<dc:creator>Perry Elliot</dc:creator>
<dc:creator>Hugh Calkins</dc:creator>
<dc:creator>Katherine C Wu</dc:creator>
<dc:creator>Cynthia A James</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers</dc:title>
<dc:identifier>pmid:39011630</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae409</dc:identifier>
</item>
<item>
<title>Anticoagulation for transient atrial fibrillation post-coronary bypass: high quality evidence needed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae402. doi: 10.1093/eurheartj/ehae402. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011559</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae402>10.1093/eurheartj/ehae402</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011559</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Felicita Andreotti</dc:creator>
<dc:creator>Raffaele De Caterina</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation for transient atrial fibrillation post-coronary bypass: high quality evidence needed</dc:title>
<dc:identifier>pmid:39011559</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae402</dc:identifier>
</item>
<item>
<title>Sudden cardiac death risk stratification in heritable cardiomyopathies: phenotype-based to genotype-based risk scores</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39011555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae381. doi: 10.1093/eurheartj/ehae381. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39011555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39011555</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae381>10.1093/eurheartj/ehae381</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39011555</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rafik Tadros</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sudden cardiac death risk stratification in heritable cardiomyopathies: phenotype-based to genotype-based risk scores</dc:title>
<dc:identifier>pmid:39011555</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae381</dc:identifier>
</item>
<item>
<title>Triaging early discharge for pulmonary embolism: home is where the heart(/lung) is</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39010836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae358. doi: 10.1093/eurheartj/ehae358. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39010836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39010836</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae358>10.1093/eurheartj/ehae358</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39010836</guid>
<pubDate>Tue, 16 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kushal T Kadakia</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-07-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Triaging early discharge for pulmonary embolism: home is where the heart(/lung) is</dc:title>
<dc:identifier>pmid:39010836</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae358</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: The prognostic value of coronary inflammation in patients with non-obstructive coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39010255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 16:ehae430. doi: 10.1093/eurheartj/ehae430. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39010255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39010255</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae430>10.1093/eurheartj/ehae430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39010255</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: The prognostic value of coronary inflammation in patients with non-obstructive coronary artery disease</dc:title>
<dc:identifier>pmid:39010255</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae430</dc:identifier>
</item>
<item>
<title>Cardiac involvement in Chagas disease and African trypanosomiasis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39009679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>Trypanosomiases are diseases caused by various species of protozoan parasite in the genus Trypanosoma, each presenting with distinct clinical manifestations and prognoses. Infections can affect multiple organs, with Trypanosoma cruzi predominantly affecting the heart and digestive system, leading to American trypanosomiasis or Chagas disease, and Trypanosoma brucei primarily causing a disease of the central nervous system known as human African trypanosomiasis or sleeping sickness. In this...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 15. doi: 10.1038/s41569-024-01057-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Trypanosomiases are diseases caused by various species of protozoan parasite in the genus Trypanosoma, each presenting with distinct clinical manifestations and prognoses. Infections can affect multiple organs, with Trypanosoma cruzi predominantly affecting the heart and digestive system, leading to American trypanosomiasis or Chagas disease, and Trypanosoma brucei primarily causing a disease of the central nervous system known as human African trypanosomiasis or sleeping sickness. In this Review, we discuss the effects of these infections on the heart, with particular emphasis on Chagas disease, which continues to be a leading cause of cardiomyopathy in Latin America. The epidemiology of Chagas disease has changed substantially since 1990 owing to the emigration of over 30 million Latin American citizens, primarily to Europe and the USA. This movement of people has led to the global dissemination of individuals infected with T. cruzi. Therefore, cardiologists worldwide must familiarize themselves with Chagas disease and the severe, chronic manifestation - Chagas cardiomyopathy - because of the expanded prevalence of this disease beyond traditional endemic regions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39009679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39009679</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01057-3>10.1038/s41569-024-01057-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39009679</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ester Cerdeira Sabino</dc:creator>
<dc:creator>Maria Carmo P Nunes</dc:creator>
<dc:creator>Johannes Blum</dc:creator>
<dc:creator>Israel Molina</dc:creator>
<dc:creator>Antonio Luiz P Ribeiro</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiac involvement in Chagas disease and African trypanosomiasis</dc:title>
<dc:identifier>pmid:39009679</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01057-3</dc:identifier>
</item>
<item>
<title>Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>Our research investigates the societal implications of access to glucagon-like peptide-1 (GLP-1) agonists, particularly in light of recent clinical trials demonstrating the efficacy of semaglutide in reducing cardiovascular mortality. A decade-long analysis of Google Trends indicates a significant increase in searches for GLP-1 agonists, primarily in North America. This trend contrasts with the global prevalence of obesity. Given the high cost of GLP-1 agonists, a critical question arises: Will...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):171-173. doi: 10.1161/CIRCULATIONAHA.124.069680. Epub 2024 Jul 15.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Our research investigates the societal implications of access to glucagon-like peptide-1 (GLP-1) agonists, particularly in light of recent clinical trials demonstrating the efficacy of semaglutide in reducing cardiovascular mortality. A decade-long analysis of Google Trends indicates a significant increase in searches for GLP-1 agonists, primarily in North America. This trend contrasts with the global prevalence of obesity. Given the high cost of GLP-1 agonists, a critical question arises: Will this disparity in medication accessibility exacerbate the global health equity gap in obesity treatment? This viewpoint explores strategies to address the health equity gap exacerbated by this emerging medication. Because GLP-1 agonists hold the potential to become a cornerstone in obesity treatment, ensuring equitable access is a pressing public health concern.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39008562</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069680>10.1161/CIRCULATIONAHA.124.069680</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008562</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Zahra Azizi</dc:creator>
<dc:creator>Fatima Rodriguez</dc:creator>
<dc:creator>Themistocles L Assimes</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide</dc:title>
<dc:identifier>pmid:39008562</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069680</dc:identifier>
</item>
<item>
<title>Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):250-252. doi: 10.1161/CIRCULATIONAHA.124.069582. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39008561</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069582>10.1161/CIRCULATIONAHA.124.069582</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008561</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jelani K Grant</dc:creator>
<dc:creator>Seth S Martin</dc:creator>
<dc:creator>Sui Zhang</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Roger S Blumenthal</dc:creator>
<dc:creator>Ron C Hoogeveen</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Josef Coresh</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study</dc:title>
<dc:identifier>pmid:39008561</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069582</dc:identifier>
</item>
<item>
<title>Working to Promote Health Equity: The Fourth Annual Disparities Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):169-170. doi: 10.1161/CIRCULATIONAHA.124.070825. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39008560</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070825>10.1161/CIRCULATIONAHA.124.070825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008560</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Latha Palaniappan</dc:creator>
<dc:creator>Karol Watson</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Working to Promote Health Equity: The Fourth Annual Disparities Issue</dc:title>
<dc:identifier>pmid:39008560</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070825</dc:identifier>
</item>
<item>
<title>Dietary Acculturation Is Associated With Altered Gut Microbiome, Circulating Metabolites, and Cardiovascular Disease Risk in US Hispanics and Latinos: Results From HCHS/SOL</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008559/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among US Hispanic and Latino adults, greater dietary acculturation was associated with elevated CVD risk, possibly through alterations in gut microbiota and related metabolites. Diet and microbiota-targeted interventions may offer opportunities to mitigate CVD burdens of dietary acculturation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):215-229. doi: 10.1161/CIRCULATIONAHA.124.069824. Epub 2024 Jun 19.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Dietary acculturation, or adoption of dominant culture diet by migrant groups, influences human health. We aimed to examine dietary acculturation and its relationships with cardiovascular disease (CVD), gut microbiota, and blood metabolites among US Hispanic and Latino adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the HCHS/SOL (Hispanic Community Health Study/Study of Latinos), US exposure was defined by years in the United States (50 states and Washington, DC) and US nativity. A dietary acculturation pattern was derived from 14 172 participants with two 24-hour dietary recalls at baseline (2008-2011) using least absolute shrinkage and selection operator regression, with food groups as predictors of US exposure. We evaluated associations of dietary acculturation with incident CVD across ≈7 years of follow-up (n=211/14 172 cases/total) and gut microbiota (n=2349; visit 2, 2014 to 2017). Serum metabolites associated with both dietary acculturation-related gut microbiota (n=694) and incident CVD (n=108/5256 cases/total) were used as proxy measures to assess the association of diet-related gut microbiome with incident CVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified an empirical US-oriented dietary acculturation score that increased with US exposure. Higher dietary acculturation score was associated with higher risk of incident CVD (hazard ratio per SD, 1.33 [95% CI, 1.13-1.57]), adjusted for sociodemographic, lifestyle, and clinical factors. Sixty-nine microbial species (17 enriched from diverse species, 52 depleted mainly from fiber-utilizing <i>Clostridia</i> and <i>Prevotella</i> species) were associated with dietary acculturation, driven by lower intakes of whole grains, beans, and fruits and higher intakes of refined grains. Twenty-five metabolites, involved predominantly in fatty acid and glycerophospholipid metabolism (eg, branched-chain 14:0 dicarboxylic acid** and glycerophosphoethanolamine), were associated with both diet acculturation-related gut microbiota and incident CVD. Proxy association analysis based on these metabolites suggested a positive relationship between diet acculturation-related microbiome and risk of CVD (<i>r</i>=0.70, <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among US Hispanic and Latino adults, greater dietary acculturation was associated with elevated CVD risk, possibly through alterations in gut microbiota and related metabolites. Diet and microbiota-targeted interventions may offer opportunities to mitigate CVD burdens of dietary acculturation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008559/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39008559</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069824>10.1161/CIRCULATIONAHA.124.069824</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008559</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Wang</dc:creator>
<dc:creator>Guo-Chong Chen</dc:creator>
<dc:creator>Zheng Wang</dc:creator>
<dc:creator>Kai Luo</dc:creator>
<dc:creator>Yanbo Zhang</dc:creator>
<dc:creator>Yang Li</dc:creator>
<dc:creator>Amanda C McClain</dc:creator>
<dc:creator>Marta M Jankowska</dc:creator>
<dc:creator>Krista M Perreira</dc:creator>
<dc:creator>Josiemer Mattei</dc:creator>
<dc:creator>Carmen R Isasi</dc:creator>
<dc:creator>Maria M Llabre</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Linda Van Horn</dc:creator>
<dc:creator>David Goldsztajn Farelo</dc:creator>
<dc:creator>Luis E Maldonado</dc:creator>
<dc:creator>Steven R Levine</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Rob Knight</dc:creator>
<dc:creator>Robert D Burk</dc:creator>
<dc:creator>Robert C Kaplan</dc:creator>
<dc:creator>Qibin Qi</dc:creator>
<dc:creator>Brandilyn A Peters</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dietary Acculturation Is Associated With Altered Gut Microbiome, Circulating Metabolites, and Cardiovascular Disease Risk in US Hispanics and Latinos: Results From HCHS/SOL</dc:title>
<dc:identifier>pmid:39008559</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069824</dc:identifier>
</item>
<item>
<title>Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39008558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240717061037&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 16;150(3):243-245. doi: 10.1161/CIRCULATIONAHA.124.069083. Epub 2024 Jul 15.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39008558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240717061037&v=2.18.0.post9+e462414">39008558</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069083>10.1161/CIRCULATIONAHA.124.069083</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39008558</guid>
<pubDate>Mon, 15 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Nancy Song</dc:creator>
<dc:creator>Tariku J Beyene</dc:creator>
<dc:creator>Daniel K Amponsah</dc:creator>
<dc:creator>Steven M Asch</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:creator>Celina M Yong</dc:creator>
<dc:date>2024-07-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Novel Use of Z Codes to Identify Social Determinants of Cardiovascular Disease Outcomes</dc:title>
<dc:identifier>pmid:39008558</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069083</dc:identifier>
</item>





























</channel>
</rss>